Adults and children with cystic fibrosis (CF) frequently have moderate to severe gastrointestinal (GI) symptoms such as fullness and…
Articles by Somi Igbene, PhD
Pulmonary exacerbations — the flares that cause a sudden worsening in respiratory symptoms — contribute to the higher mortality and…
Trikafta, a triple therapy combining elexacaftor, tezacaftor, and ivacaftor, cleared Aspergillus fungus in the lungs and prevented severe infections…
The Phase 1 clinical trial into the safety and pharmacological properties of the antibiotic Xenleta (lefamulin) in adults with…
Avecris and Nosis Biological Sciences have won the Cystic Fibrosis (CF) Foundation’s inaugural “Golden Ticket” Competition. The companies…
Gut bacteria entering the lungs during acid reflux episodes may promote lung inflammation and poorer lung function in cystic…
Regular use of antibiotics to treat persistent infections is linked with hypersensitivity reactions in individuals with cystic fibrosis (CF),…
Instead of stopping Trikafta treatment, reducing the dose and providing psychological support may reduce or resolve mental health side…
Health Canada has approved Vertex Pharmaceuticals’ Kalydeco (ivacaftor) to treat cystic fibrosis (CF) in patients 4 months…
Kalydeco (ivacaftor) therapy, given before age 1, was shown to normalize sweat chloride levels, and improve growth and lung…